These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 23083681)

  • 1. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
    Zhong J; Rao X; Rajagopalan S
    Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
    Mulvihill EE
    Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis.
    Mulvihill EE; Varin EM; Gladanac B; Campbell JE; Ussher JR; Baggio LL; Yusta B; Ayala J; Burmeister MA; Matthews D; Bang KWA; Ayala JE; Drucker DJ
    Cell Metab; 2017 Jan; 25(1):152-165. PubMed ID: 27839908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of incretins in diabetes.
    Advani A; Bugyei-Twum A; Connelly KA
    Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.
    Ohara-Nemoto Y; Nakasato M; Shimoyama Y; Baba TT; Kobayakawa T; Ono T; Yaegashi T; Kimura S; Nemoto TK
    Infect Immun; 2017 Sep; 85(9):. PubMed ID: 28630069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin effect: GLP-1, GIP, DPP4.
    Kazafeos K
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
    Klemann C; Wagner L; Stephan M; von Hörsten S
    Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
    Zhong J; Maiseyeu A; Davis SN; Rajagopalan S
    Circ Res; 2015 Apr; 116(8):1491-504. PubMed ID: 25858071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research.
    Hocher B; Reichetzeder C; Alter ML
    Kidney Blood Press Res; 2012; 36(1):65-84. PubMed ID: 22947920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.
    Mentlein R
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):443-52. PubMed ID: 19748062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.
    Chrysant SG; Chrysant GS
    Am J Cardiol; 2012 Jun; 109(11):1681-5. PubMed ID: 22425330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence.
    Pala L; Rotella CM
    J Diabetes Res; 2013; 2013():590456. PubMed ID: 23853775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.
    Hirano T; Mori Y
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):80-6. PubMed ID: 27186361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB
    Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
    Xie W; Song X; Liu Z
    Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.
    Gong Q; Rajagopalan S; Zhong J
    Int J Cardiol; 2015 Oct; 197():170-9. PubMed ID: 26142202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
    Fadini GP; Avogaro A
    Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.